Is Dificid in shortage in 2026? Get the latest update on Dificid (Fidaxomicin) availability, cost, generic options, and what patients can do right now.
If you've been told your pharmacy can't get Dificid (Fidaxomicin), you might be wondering: is there a Dificid shortage? The answer is a little more nuanced than a simple yes or no.
In this article, we'll give you the latest information on Dificid availability in 2026, explain why it's been hard to find, break down what it costs now, and share what you can do to get your prescription filled.
As of early 2026, Dificid is not officially listed on the FDA's drug shortage database. That means there isn't a manufacturing or supply chain shortage in the traditional sense.
However, many patients still report difficulty finding Dificid at their local pharmacy. The reason isn't a shortage of the drug itself — it's a stocking and access problem. Many pharmacies simply don't carry it because of the extreme cost and relatively low prescription volume compared to common medications.
The situation improved significantly in July 2025 when Teva launched the first generic version of Fidaxomicin. The generic is more affordable, making pharmacies more willing to stock it. But the transition is still ongoing, and availability varies by location.
Several factors make Dificid challenging to locate:
Brand-name Dificid costs between $5,100 and $6,550 for a single 10-day course (20 tablets). Even with the generic now available at approximately $1,290 to $1,800 with coupons, it remains one of the more expensive antibiotics on the market. Many retail pharmacies don't want to tie up thousands of dollars in inventory for a medication they may only dispense a few times per month.
Most insurance plans require prior authorization before covering Dificid. Many also require step therapy — your doctor must show that you've tried oral Vancomycin first (or explain why it's not appropriate). These requirements add delays and uncertainty, which discourages pharmacies from stocking the drug speculatively.
The 2021 IDSA/SHEA guideline update elevated Fidaxomicin to first-line treatment for C. diff infections alongside Vancomycin. This increased prescription volume, but pharmacy stocking hasn't fully caught up.
Some insurance plans require Dificid to be dispensed through a specialty pharmacy rather than a regular retail pharmacy. If you're at the wrong type of pharmacy for your plan, you'll be turned away even if the drug is technically available there.
For a deeper look at these challenges, read our article: Why Is Dificid So Hard to Find?
Here's a breakdown of current pricing:
For a complete breakdown of ways to save, read our guide to saving money on Dificid.
The biggest development is the Teva generic Fidaxomicin, launched in July 2025. This AB-rated generic is therapeutically equivalent to brand-name Dificid and is substantially cheaper. As more pharmacies adopt the generic, availability should continue to improve throughout 2026.
For patients with recurrent C. diff, newer treatments like Vowst (oral fecal microbiota spores) and Rebyota (rectally administered fecal microbiota) are becoming more established. These aren't replacements for Dificid — they're used after antibiotic treatment to restore gut bacteria and prevent recurrence. Learn about all options in our alternatives guide.
Here's a step-by-step plan:
For detailed strategies, see our full guide: How to Find Dificid in Stock Near You.
While Dificid isn't in a formal FDA-listed shortage, real-world availability remains a challenge for many patients in 2026. The good news is that the generic launch in 2025 is steadily improving the landscape, and there are more tools and options available than ever before.
If you're struggling to find Dificid, don't wait — C. diff infections need prompt treatment. Use Medfinder to check real-time pharmacy availability, explore savings programs to reduce costs, and keep your doctor informed so they can help you get the treatment you need.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
